Although the application of ICB has greatly improved the prognosis of those with immuno-hot tumors, a large proportion of NSCLC patients with EGFR WT and immuno-cold tumors still lack effective treatment strategies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.